Incendia Therapeutics is a precision oncology biotech company focused on reprogramming the tumor microenvironment to enhance the efficacy of immuno-oncology therapies. Their lead product, PRTH-101, is a monoclonal antibody targeting Discoidin Domain Receptor 1 (DDR1), which is implicated in creating barriers that prevent immune cells from attacking tumors. By disrupting these barriers, Incendia aims to improve the effectiveness of existing cancer treatments and address recalcitrant cancers. The company is currently conducting a Phase 1 clinical trial for PRTH-101, indicating a strong commitment to advancing their innovative approach in the competitive oncology market.

Operations

Cambridge, MA, USA

Boston, MA, USA

West Street / River Street, Boston, MA, USA

Incendia Therapeutics

KdT Ventures is a new age seed stage venture firm, with a focus on the intersection of technology and science.

KdT Ventures LLC

KdT Ventures

Discover available job opportunities within our portfolio

Tell us about your professional DNA to get discovered by any company in our network with opportunities relevant to your career goals.

Leverage our network to build your career.

#### Welcome!

Thank you for joining KdT Ventures Network!

To help us best support you in your search, please take a few minutes to tell us about what you are looking for in your next role. We’ll use this information to connect you to relevant opportunities in the KdT Ventures network as they come up.

You can always update this information later.

Welcome to the KdT Ventures talent network

As our companies grow, they look to us to help them find the best talent.

Signal that you'd be interested in working with a KdT Ventures company to help us put the right opportunities at great companies on your radar. The choice to pursue a new career move is then up to you.

Join Us